{"id":1773,"date":"2012-09-01T12:01:00","date_gmt":"2012-09-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/marktruecknahme-von-alemtuzumab-aus-kommerziellen-gruenden-ein-praezedenzfall"},"modified":"2012-09-01T12:01:00","modified_gmt":"2012-09-01T10:01:00","slug":"marktruecknahme-von-alemtuzumab-aus-kommerziellen-gruenden-ein-praezedenzfall","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/marktruecknahme-von-alemtuzumab-aus-kommerziellen-gruenden-ein-praezedenzfall","title":{"rendered":"Marktr\u00fccknahme von Alemtuzumab aus kommerziellen Gr\u00fcnden \u2013 ein Pr\u00e4zedenzfall"},"content":{"rendered":"<p>\u201eDas Dilemma von Genzyme: Sein billiges Krebsmedikament (Anmerkung der Redaktion: Alemtuzumab = MabCampath\u00ae) m\u00f6chte einen potenziellen Blockbuster f\u00fcr Multiple Sklerose kannibalisieren\u201d. Unter dieser \u00dcberschrift berichtete bereits im Jahr 2010 der Journalist Jim Edwards f\u00fcr CBS Interactive Inc. \u00fcber einen potenziell neuen Wirkstoff zur Behandlung der Multiplen Sklerose (MS): Alemtuzumab (MabCampath\u00ae; 1). Genzyme, inzwischen Tochterunternehmen der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201eDas Dilemma von Genzyme: Sein billiges Krebsmedikament (Anmerkung der Redaktion: Alemtuzumab = MabCampath\u00ae) m\u00f6chte einen potenziellen Blockbuster f\u00fcr Multiple Sklerose kannibalisieren\u201d. Unter dieser \u00dcberschrift berichtete bereits im Jahr 2010 der Journalist Jim Edwards f\u00fcr CBS Interactive Inc. \u00fcber einen potenziell neuen Wirkstoff zur Behandlung der Multiplen Sklerose (MS): Alemtuzumab (MabCampath\u00ae; 1). Genzyme, inzwischen Tochterunternehmen der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2296,3954,3953,799,352,843,846],"class_list":["post-1773","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alemtuzumab","tag-camms223-studie","tag-care-ms-studien","tag-chronische-lymphatische-leukaemie","tag-multiple-sklerose","tag-pharmaindustrie","tag-pharmazeutische-unternehmer"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1773"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1773\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}